Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial
15. Juni 2022 09:00 ET
|
Rénibus Therapeutics Inc.
RBT-1 met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic...
Renibus Therapeutics Expands Leadership Team, Announces Appointments of New Chief Financial Officer and Chief Medical Officer
02. Juni 2022 09:00 ET
|
Rénibus Therapeutics Inc.
Jamie Donadio appointed Chief Financial Officer and Bhupinder Singh, MD, appointed Chief Medical Officer Appointments bring more than 40 combined years of proven leadership, clinical and commercial...
Renibus Therapeutics Strengthens IP Position with Additional US Patent
13. April 2022 08:00 ET
|
Rénibus Therapeutics Inc.
SOUTHLAKE, Texas, April 13, 2022 (GLOBE NEWSWIRE) -- Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today...
Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding
15. Februar 2022 09:00 ET
|
Rénibus Therapeutics Inc.
Founder, CEO and healthcare venture capitalist, Stonebanks brings 25 years of experience to Renibus leadership team Renibus closes $35 million Series A; Funds will be used to advance the development...
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021
28. Oktober 2021 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present abstracts at the American Society of...
Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury
11. März 2021 09:00 ET
|
Rénibus Therapeutics Inc.
- Renibus plans to enroll 126 subjects at up to 20 sites across the United States, Canada, Australia, and New Zealand DALLAS, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics®...
Rénibus Therapeutics to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference
25. Februar 2021 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Rénibus Therapeutics, Inc., a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease,...
Renibus Therapeutics Announces Publication of Positive Results of RBT-3 Experimental Preclinical Studies in Scientific Journal Nephrology Dialysis Transplant
16. Februar 2021 09:00 ET
|
Rénibus Therapeutics Inc.
-With no currently approved therapies for the prevention or treatment of platinum-induced toxicity, RBT-3 has the potential to fill a critical unmet medical need Dallas, Texas, Feb. 16, 2021 ...
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020
19. Oktober 2020 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of...
Renibus Therapeutics’ COVID-19 Treatment, RBT-9, Shows Antiviral Activity Against SARS-CoV-2 In Vitro
07. Oktober 2020 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that its investigational treatment for COVID-19, RBT-9, has...